Understanding how a specific molecule behaves during complex biological processes is a challenge facing biomedical research, despite major biotechnological progress…
Parkinson’s Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-β-Cyclodextrin Treatment See our latest Publication Background The…
OrganoTherapeutics won the Rising Startup competition at Biovaria 2021 BioVaria Startup Awards go to iRASP Therapeutics and OrganoTherapeutics 30 April…
OrganoTherapeutics received support from the Luxembourgish Ministry of Economy for the project “Drug repurposing to target SARS-CoV-2 brain infection”. In…
The article “Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening”…
We are very happy to announce that OrganoTherapeutics has been accepted into the Creative Destruction Lab (CDL) program (https://www.linkedin.com/company/creative-destruction-lab/). We…